Effects of Bothrops snake bites on blood clotting factors in the French Caribbean
Abnormalities of Plasma Willebrand Factor Activity Induced by Bothrops Snakebites Endemic to Martinique and French Guyana
This study looks at how bites from Bothrops snakes affect blood clotting in people from Martinique and French Guiana to help improve treatment for snakebite victims.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital Center of Martinique Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Fort-de-France, Martinique) |
| Trial ID | NCT06304714 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the impact of Bothrops snake envenomation on von Willebrand factor activity in patients from Martinique and French Guiana. It aims to understand the coagulopathy and hemorrhagic complications associated with snake bites, which are a significant health concern in these regions. The study will involve patients who have suffered confirmed envenomations and will assess their clinical symptoms and laboratory findings to better understand the effects of the venom. The findings could inform treatment protocols and improve patient outcomes in snakebite cases.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been admitted to the emergency department with confirmed Bothrops snake bites and exhibit severe envenomation symptoms.
Not a fit: Patients who have not suffered a snakebite or those with mild envenomation symptoms may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for snakebite victims, potentially reducing complications and mortality rates.
How similar studies have performed: While there is limited data on similar studies, the focus on snakebite envenomation and its effects on coagulation factors is a relatively novel area of investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men or Women, at least 18 years old * Be admitted to the Emergency Department of the Martinique University Hospital or the Cayenne University Hospital * Be the victim of a confirmed Bothrops snake bite in Martinique or French Guyana. The formal identification of the snake by the patient or his entourage is imperative. * Have a confirmed diagnosis of stage III envenomation (regional oedema of the limb and/or moderate general symptoms such as moderate hypotension, malaise, vomiting, abdominal pain, diarrhoea) and stage IV (extensive oedema reaching the trunk and/or severe general symptoms such as prolonged hypotension, shock, anaphylactoid reaction, visceral damage) * Be able to receive and understand information related to the research * Be able to freely give verbal consent to participate in the proposed research * Be able to freely give written informed consent to participate in the plasmathèque * Be affiliated to the general social security system Exclusion Criteria: * Pregnant or breastfeeding woman * People who have been treated for snakebite with Bothrops anti-venom Bothrofav® or Antivipmyn-tri®. * Known disorders of haemostasis such as haemophilia A (factor VIII deficiency), haemophilia B (factor IX deficiency), vitamin K deficiency, hepato-cellular insufficiency, presence of circulating anticoagulant factors * Disseminated intravascular coagulation (DIC) * Constitutional and acquired Von Willebrand disease * Constitutional and acquired thrombopathies * Idiopathic thrombocytopenic purpura * Person under legal protection (guardianship, curatorship, safeguard of justice), and person deprived of liberty.
Where this trial is running
Fort-de-France, Martinique
- University Hospital Center of Martinique — Fort-de-France, Martinique, Martinique (Recruiting)
Study contacts
- Principal investigator: DABOR RESIERE, Professor — University Hospital of Martinique
- Study coordinator: Sebastien Cavalini
- Email: sebastien.cavalini@chu-martinique.fr
- Phone: +596596592696
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.